Circulating damage marker profiles support a neuroprotective effect of erythropoietin in ischemic stroke patients

Molecular Medicine

Volumn 17, Issue 11, 2011, Pages 1306-1310

  Ehrenreich, Hannelore ^a   Kästner, Anne ^a   Weissenborn, Karin ^b   Streeter, Jackson ^c   Sperling, Swetlana ^a   Wang, Kevin K ^c   Worthmann, Hans ^b   Hayes, Ronald L ^c   von Ahsen, Nico ^d   Kastrup, Andreas ^e   Jeromin, Andreas ^c   Herrmann, Manfred ^f  

^a MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c BANYAN BIOMARKERS INC   (United States)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

^e KLINIKUM BREMEN OST   (Germany)

^f UNIVERSITY OF BREMEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GLIAL FIBRILLARY ACIDIC PROTEIN; PLACEBO; PROTEIN S100B; RECOMBINANT ERYTHROPOIETIN; UBIQUITIN THIOLESTERASE;

AGED; ARTICLE; BLOOD SAMPLING; BRAIN ISCHEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NERVE CELL LESION; NEUROPROTECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL;

AGED; AREA UNDER CURVE; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; ERYTHROPOIETIN; FEMALE; HUMANS; MALE; NEUROPROTECTIVE AGENTS; RECOMBINANT PROTEINS; STROKE; TREATMENT OUTCOME;

EID: 81755172624     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2011.00259     Document Type: Article

References (19)

1. Brines M, Cerami A. (2005) Emerging biological roles for erythropoietin in the nervous system. Nat. Rev. Neurosci. 6:484-94.
2. Sargin D, Friedrichs H, El-Kordi A, Ehrenreich H. (2010) Erythropoietin as neuroprotective and neuroregenerative treatment strategy: comprehensive overview of 12 years of preclinical and clinical research. Best Pract. Res. Clin. Anaestesiol. 24:573-94.
3. Ehrenreich H, et al. (2002) Erythropoietin therapy for acute stroke is both safe and beneficial. Mol. Med. 8:495-505.
4. Ehrenreich H, et al. (2009) Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke. 40:e647-56.
5. Jia L, Chopp M, Zhang L, Lu M, Zhang Z. (2010) Erythropoietin in combination of tissue plasminogen activator exacerbates brain hemorrhage when treatment is initiated 6 hours after stroke. Stroke. 41:2071-6.
6. Zechariah A, ElAli A, Hermann DM. (2010) Combination of tissue-plasminogen activator with erythropoietin induces blood-brain barrier permeability, extracellular matrix disaggregation, and DNA fragmentation after focal cerebral ischemia in mice. Stroke. 41:1008-12.
7. Herrmann M, Vos P, Wunderlich MT, de Bruijn CH, Lamers KJ. (2000) Release of glial tissuespecific proteins after acute stroke: a comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein. Stroke. 31:2670-7.
8. Papa L, et al. (2010) Ubiquitin C-terminal hydrolase is a novel biomarker in humans for severe traumatic brain injury. Crit. Care Med. 38:138-44.
9. Lewis SB, et al. (2010) Identification and preliminary characterization of ubiquitin C terminal hydrolase 1 (UCHL1) as a biomarker of neuronal loss in aneurysmal subarachnoid hemorrhage. J. Neurosci. Res. 88:1475-84.
10. Liu MC, et al. (2010) Ubiquitin C-terminal hydrolase-L1 as a biomarker for ischemic and traumatic brain injury in rats. Eur. J. Neurosci. 31:722-32.
11. Siman R, et al. (2008) Biomarker evidence for mild central nervous system injury after surgically-induced circulation arrest. Brain Res. 1213:1-11.
12. Siman R, et al. (2009) A panel of neuron-enriched proteins as markers for traumatic brain injury in humans. J. Neurotrauma. 26:1867-77.
13. Heizmann CW. (1999) Ca2+-binding S100 proteins in the central nervous system. Neurochem. Res. 24:1097-100.
14. Wunderlich MT, et al. (1999) Early neurobehavioral outcome after stroke is related to release of neurobiochemical markers of brain damage. Stroke. 30:1190-5.
15. Marchi N, et al. (2003) Peripheral markers of brain damage and blood-brain barrier dysfunction. Restor. Neurol. Neurosci. 21:109-21.
16. Eng LF, Ghirnikar RS, Lee YL. (2000) Glial fibrillary acidic protein: GFAP-thirty-one years (1969-2000). Neurochem. Res. 25:1439-51.
17. Herrmann M, et al. (2000) Neurobehavioral outcome prediction after cardiac surgery: role of neurobiochemical markers of damage to neuronal and glial brain tissue. Stroke. 31:645-50.
18. Pelinka LE, et al. (2004) GFAP versus S100B in serum after traumatic brain injury: relationship to brain damage and outcome. J. Neurotrauma. 21:1553-61.
19. Herrmann M, Ehrenreich H. (2003) Brain derived proteins as markers of acute stroke: their relation to pathophysiology, outcome prediction and neuroprotective drug monitoring. Restor. Neurol. Neurosci. 21:177-90.